Illumina, Inc.

ILMN

$376.35

+12.55% (1 year change)

Avg closing price

Price range

Market Cap

$53.4 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$794 Million

Total revenue in the last quarter.

Net Income

$179 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$4.30

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

83.77x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$162 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Illumina, Inc.

News

Global Cell Analysis Market (2020 to 2027) - Featuring Danaher, Illumina & Merck Among Others - ResearchAndMarkets.com

Global Cell Analysis Market (2020 to 2027) - Featuring Danaher, Illumina & Merck Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell Analysis Global Market - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The cell analysis global market is expected to reach $33,54...

Business Wire Business Wire, 2 days ago
Illumina, Helix track spread of more contagious coronavirus variant - MedCity News

Illumina, Helix track spread of more contagious coronavirus variant - MedCity News

The two companies are working together to detect instances of the more contagious B.1.1.7 variant in the U.S. After Colorado identified the first case in the U.S. on Dec. 28, more than 60 cases hav...

MedCity News MedCity News, 5 days ago
Former FDA chief Scott Gottlieb on Pfizer vaccine's ability to neutralize Covid variants

Former FDA chief Scott Gottlieb on Pfizer vaccine's ability to neutralize Covid variants

A coronavirus vaccine developed by Pfizer and BioNTech appears to be effective against a key mutation in the more infectious variants of the virus discovered in the U.K. and South Africa, according...

Flipboard Flipboard, 8 days ago